Trust me, Pfizer isn't interested in buying BMS, analyst says—at least not yet

Investors who have been waiting to see whether serial acquirer Pfizer would strike a megadeal for Bristol-Myers Squibb can cool it, one analyst says.

The Big Pharma isn’t interested in snagging its immuno-oncology rival, Citi analyst Andrew Baum wrote to clients in a note seen by The Fly, stressing that Pfizer CEO Ian Read made clear to him that the company doesn’t want Bristol unless it either brings along some transformational data or gets cheaper.